Remedy pushes back against BG3 dev's criticism of Epic's game publishing

Remedy Entertainment publicly defended Epic Games and CEO Tim Sweeney after criticism that Epic-funded exclusivity for Alan Wake 2 cost the studio substantial sales; Remedy says the Epic publishing deal was fair and that Alan Wake 2 likely would not have existed without Epic. The studio has faced measurable financial strain—its co-op title FBC: Firebreak flopped last summer, it issued an October profit warning, reported unsatisfactory Q3 2025 results, and CEO Tero Virtala subsequently stepped down—and Alan Wake 2 only reached profitability about 18 months after its 2023 launch when sales exceeded 2 million copies. Critics argue Epic's smaller PC user base (roughly 55–60% of Steam) and exclusivity likely reduced total sales, a point that could inform investor views on platform-exclusivity deals and publisher financing in the games sector.

Analysis

Market structure: Epic’s publishing model is a built-in liquidity source for mid-size studios (explicit winner) while platform exclusivity reduces addressable Steam audiences (implicit loser: Steam-heavy sellers). If Epic converts even 10–20% more mid-tier releases to timed exclusives over 2–3 years, Valve’s PC market share could compress by ~5–10pp and shift ~5–15% of near-term PC revenue toward upfront-guarantee-funded deals. Hardware vendors (NVDA/AMD) and large multi-channel publishers (MSFT/EA/TTWO) are neutral-to-positive as demand stays broadly diversified.

Risk assessment: Tail risks include antitrust/regulatory action vs. exclusivity bundling (EU/US investigations within 6–18 months) and developer reputational backlash that reduces future deal flow; a regulatory ruling forcing greater platform interoperability would rapidly re-rate Epic’s economics. Short-term (days–weeks) noise around PR and sales spikes; medium-term (3–12 months) revenue recognition and earnings volatility for studios; long-term (2–5 years) structural rebalancing of funding vs. distribution power.

Trade implications: Favor large-cap, multi-channel publishers and gaming-adjacent hardware: long MSFT, TTWO, NVDA; avoid or hedge small-cap, Steam-dependent publishers (select shorts/puts on EMBRAC B or similar). Use 3–9 month options (buy call spreads on NVDA/MSFT to capture secular upside; buy puts on EMBRAC B 10% OTM 3-month tenors as downside protection) and size bets 1–3% of portfolio.

Contrarian angles: Consensus fixates on “lost Steam sales” but underestimates non-linear value of upfront funding and IP enablement—many mid-size studios wouldn’t ship without guarantees, capping downside for Epic-funded partners. Market may be underpricing regulatory risk and consumer friction; if Epic improves client UX materially over 12–24 months, exclusivity fears will fade and valuations of funded studios could re-rate higher.

Key Decisions for Investors

• Establish a 2–3% long position in Microsoft (MSFT) over 12–24 months to capture Activision/IP consolidation; accumulate on pullbacks >5% within next 90 days, target +20–30% upside.
• Allocate 1–2% to a 6–9 month NVDA call spread (buy 10% ITM call, sell 30% OTM call) to express secular GPU demand while capping premium outlay; roll or take profits if NVDA rises >25% or implied vol spikes >40%.
• Initiate a 1–2% long position in Remedy (HE:REMEDY) on any >15% price drop or improved guidance / sale milestone, with a 12-month target +30%; fund by shorting 1–2% of Embracer (STO:EMBRAC B) or buying 3-month 10% OTM puts to express downside in debt-levered, Steam-exposed publishers.
• Purchase 3-month 10% OTM puts on small/medium-cap Steam-dependent publishers (size 0.5–1% each) as event-driven hedges; if EU/US antitrust investigations open within 30–90 days, increase protective put allocation by 50% and trim exclusivity-beneficiary longs by 25%.